How to start a menopause and HRT telehealth brand
A multi-year clinical relationship sold as a subscription. Lighter than TRT operationally, and almost entirely a retention business rather than an acquisition one.
Key takeaways
- Menopause care is symptom-led rather than lab-gated, which makes it operationally lighter than testosterone therapy.
- Any medication or delivery-form change restarts the review clock, triggering a refill intake weeks later rather than at the next quarterly date.
- Non-hormonal pathways convert patients with estrogen contraindications instead of declining them.
- Estradiol and progesterone are not controlled substances, so the state map is unconstrained.
- The business is multi-year. Portal and check-in cadence matter more than checkout conversion.
The clinical rhythm
Menopause and perimenopause care is typically estradiol delivered as a pill, patch, cream or vaginal gel, with progesterone added where the patient has an intact uterus. Non-hormonal alternatives exist for patients who cannot take estrogen.
The cadence is slower than GLP-1 and lighter than TRT: asynchronous review in most states, an early review at around month one to catch side effects, then a quarterly refill intake with dose adjustment driven by symptoms rather than by a lab gate.
The rule most platforms get wrong
Any medication change, or any change of delivery form, is not a refill. It is a protocol event, and it should trigger a refill intake review roughly four weeks later rather than waiting for the next quarterly date.
Platforms that treat a dose or form change as an ordinary refill produce two failures at once: a clinical one, because nobody checks how the patient responded to the change, and a billing one, because the cycle no longer matches what was dispensed.
Build the non-hormonal pathway on purpose
Patients with contraindications to estrogen are a meaningful share of the funnel. A brand without a non-hormonal option simply declines them, having already paid to acquire them.
Offering a non-hormonal pathway converts that traffic and, more importantly, keeps the patient in a relationship where they may become eligible for other therapies later. It is one of the clearest examples in this category of a clinical option that is also a commercial one.
Why this is a retention business
The therapy runs for years, not months. The patient's decision to continue is made repeatedly, quietly, and mostly on the basis of whether the experience feels attended to.
That puts unusual weight on infrastructure that has nothing to do with prescribing.
- A portal that shows shipments, next check-in and payment methods without a support ticket.
- Private provider messaging, so a question about a side effect does not become a cancellation.
- Self-serve card updates, because involuntary churn on a multi-year subscription is pure lost margin.
- Twelve-week billing that matches the review cadence rather than a monthly calendar.
- A recognisable statement descriptor, which you only control if you own the merchant account.
Combined protocols
Combined estrogen and testosterone protocols are supported where clinically appropriate, and are increasingly requested. Run as one program with one patient record rather than two disconnected subscriptions, they are simpler for the patient and easier to bill correctly.
The constraint to watch is that adding a scheduled component pulls the program back toward the TRT workflow, with its lab and visit requirements. That is a clinical decision, but it has an operational tail worth planning for.
Async rails, quarterly cadence, medication-change logic built in
PharmaBro runs menopause care fully asynchronously, and treats a medication or delivery-form change as a protocol event that schedules its own follow-up intake rather than waiting for the next quarterly date.
Twelve-week billing aligns with the review cadence, and the rebill engine fires on fulfillment rather than on a calendar date.
Conclusion
Menopause care is the most durable subscription in direct-to-consumer telehealth and the least dependent on acquisition cleverness.
Run it asynchronously where you can, build the non-hormonal pathway deliberately, treat medication changes as protocol events with their own review, and spend your effort on the portal rather than the checkout.
Frequently asked questions
Does HRT require labs before prescribing?
Not as a universal gate. Labs are ordered on clinical indication rather than for every patient, which is a real operational difference from testosterone therapy where baseline and quarterly panels gate the fills.
Can menopause care be delivered asynchronously?
Yes, by a provider licensed in the patient's state, with no scheduled visit anywhere in the flow.
What happens when a patient changes dose or delivery form?
It should trigger a refill intake review roughly four weeks later rather than waiting for the next quarterly cycle. Treating a change as an ordinary refill is the most common operational error in this category.
References
Priya RaghunathanHead of Compliance Operations
Handles LegitScript, HIPAA posture, MSO structuring and state coverage. Writes the parts of this blog that operators wish someone had told them before they signed.